Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

News Features

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Michael O'Riordan

January 17, 2025

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

May 12, 2023

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

News Features

Pricey Inclisiran Is Rolling Out: a ‘Buy-and-Bill’ Model May Smooth Its Path

Michael O'Riordan

January 17, 2022

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

News Features

The Hope Dealers: How Clinicians and New Tech Could End Unnecessary PAD Amputations

December 24, 2020

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

Top News in Heart Failure: 2018

News Features

Top News in Heart Failure: 2018

December 28, 2018

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

News Features

Trajectory Unknown: How ORBITA Lands in Clinical Practice Still Up for Debate

Michael O'Riordan

November 27, 2017

News Features

全年回顾：医生选出介入心脏病学等领域 2016 年的最大新闻

December 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.